Merck Hits Back At Halozyme In Cancer Drug Patent Row

By Hanna Vioque ( September 30, 2025, 6:18 PM BST) -- Merck has once again asked a London court to nix Halozyme's patents for an under-the-skin drug delivery system because they allegedly solve no technical problem in the field, as it plans to launch its own subcutaneous injectable next month. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login